
Joshua K. Sabari, MD, highlights pharmacists’ roles in coordinating access, financial assistance, and early adverse effect management for patients starting zongertinib (Hernexeos).
Joshua K. Sabari, MD, highlights pharmacists’ roles in coordinating access, financial assistance, and early adverse effect management for patients starting zongertinib (Hernexeos).
Joshua K. Sabari, MD, explains zongertinib’s (Hernexeos) favorable safety profile and quality-of-life benefits over intravenous antibody-drug conjugates in patients with HER2-mutated non-small cell lung cancer (NSCLC).
Joshua K. Sabari, MD, discusses how zongertinib’s inclusion in the National Comprehensive Care Network (NCCN) guidelines represents a game-changing second-line treatment for HER2-mutant non-small cell lung cancer (NSCLC).
Zongertinib shows promising efficacy and safety for HER2-mutant NSCLC, with a 71% response rate and low toxicity, paving the way for future treatments.
Published: June 3rd 2025 | Updated: June 11th 2025
Published: September 8th 2025 | Updated:
Published: June 3rd 2025 | Updated: June 11th 2025
Published: September 8th 2025 | Updated: